NetworkNewsBreaks – Processa Pharmaceuticals Inc
Post# of 40
(Total Views: 260)
Posted On: 10/02/2020 6:11:45 PM
NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Processa expects approximately $19.2 million in gross proceeds and announced that, in connection with the offering, its common stock has been approved for listing on the Nasdaq Capital Market with commencement of trading under the symbol “PCSA” on October 2, 2020. The offering is expected to close on October 6, 2020, subject to satisfaction of customary conditions. Processa intends to use the net proceeds of the offering to conduct clinical trials as well as for working capital and other general corporate purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Processa expects approximately $19.2 million in gross proceeds and announced that, in connection with the offering, its common stock has been approved for listing on the Nasdaq Capital Market with commencement of trading under the symbol “PCSA” on October 2, 2020. The offering is expected to close on October 6, 2020, subject to satisfaction of customary conditions. Processa intends to use the net proceeds of the offering to conduct clinical trials as well as for working capital and other general corporate purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)